AVTX Earnings Avalo Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–27 of 27
| Q2 2026 | 2026-06-30 | -1.75 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.98 | 2026-05-13 | 10-Q |
| FY 2025 | 2025-12-31 | -5.84 | 2026-03-23 | 10-K |
| Q3 2025 | 2025-09-30 | -5.47 | 2025-11-06 | 10-Q |
| Q2 2026 | 2025-06-30 | -3.18 | 2026-08-06 | 10-Q |
| Q1 2026 | 2025-03-31 | -1.25 | 2026-05-13 | 10-Q |
| FY 2025 | 2024-12-31 | -20.91 | 2026-03-23 | 10-K |
| Q3 2025 | 2024-09-30 | -22.63 | 2025-11-06 | 10-Q |
| Q2 2025 | 2024-06-30 | -30.63 | 2025-08-07 | 10-Q |
| Q1 2025 | 2024-03-31 | -141.14 | 2025-05-12 | 10-Q |
| FY 2024 | 2023-12-31 | -113.58 | 2025-03-20 | 10-K |
| Q3 2024 | 2023-09-30 | -231.05 | 2024-11-07 | 10-Q |
| Q2 2024 | 2023-06-30 | -338.85 | 2024-08-12 | 10-Q |
| Q1 2024 | 2023-03-31 | -204.00 | 2024-05-13 | 10-Q |
| FY 2023 | 2022-12-31 | -1063.00 | 2024-03-29 | 10-K |
| Q3 2023 | 2022-09-30 | -3.39 | 2023-11-09 | 10-Q |
| Q2 2023 | 2022-06-30 | -3.73 | 2023-08-03 | 10-Q |
| Q1 2023 | 2022-03-31 | -2.35 | 2023-05-04 | 10-Q |
| FY 2018 | 2018-12-31 | -1.20 | 2019-03-18 | 10-K |
| Q3 2018 | 2018-09-30 | -1.05 | 2018-11-13 | 10-Q |
| FY 2018 | 2017-12-31 | 0.42 | 2019-03-18 | 10-K |
| Q3 2018 | 2017-09-30 | 0.65 | 2018-11-13 | 10-Q |
| FY 2017 | 2017-06-30 | -0.14 | 2018-04-02 | 10-K |
| FY 2017 | 2017-03-31 | -0.19 | 2018-04-02 | 10-K |
| FY 2017 | 2016-12-31 | -1.87 | 2018-04-02 | 10-K |
| Q3 2017 | 2016-09-30 | -1.71 | 2017-11-07 | 10-Q |
| FY 2017 | 2015-12-31 | -4.71 | 2018-04-02 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.